Joint

The Joint Corp. engages in the development, ownership, operation, support, and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment consists of the operating activities of the company-owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar, and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Joint (JYNT) posts record sales in Q4 2022, eyes strategic growth

Joint (JYNT) delivered strong financial performance in Q4 2022, driven by record clinic openings and successful marketing initiatives.
While facing challenges such as labor costs and franchise sales impact, the company is focused on margin expansion and strategic growth opportunities.
With a positive outlook for 2023 revenue and adjusted EBITDA, Joint (JYNT) aims to navigate challenges and capitalize on opportunities for sustained success.
The company's commitment to patient care, operational efficiency, and financial planning positions it well for future growth and profitability.

Joint Corp. posts impressive Q1 results amidst digital marketing evolution

Joint Corp. delivered robust Q1 2023 results with strong sales growth and operational performance across its clinic network.
While facing competitive pressures and marketing challenges, the company's focus on efficiency and patient acquisition strategies bodes well for future growth.
Adapting to digital marketing trends and leveraging upcoming events can position Joint Corp. for sustained success and investor confidence.

Joint (JYNT) reports strong Q2 growth, focuses on profitability

Joint (JYNT) reported solid growth in system-wide sales and clinic openings, with profitability around 20% despite challenges.
The company is actively addressing operational issues, optimizing its clinic portfolio, and focusing on cost savings initiatives.
Strategic planning for profitability and efficiency in 2024 and beyond is underway, with a commitment to long-term success.
Partnerships, marketing expansions, and ongoing reviews present opportunities for growth and market expansion for Joint (JYNT).

The Joint Corp. reports stable Q3 earnings, shifts focus to franchises

The Joint Corp. delivered solid financial performance in Q3 2023, with a focus on refranchising and enhancing franchise clinic operations.
Efforts to boost new patient starts and optimize marketing strategies are driving positive trends in conversion rates and sales.
While facing challenges in new patient counts and franchise sales, the company is strategically positioning itself for long-term success.

The Joint Corp. reports robust 2023 performance and strategic growth plans

The Joint Corp. delivered strong financial performance in 2023, with notable growth in sales, revenue, and patient metrics.
Strategic initiatives like refranchising and local store marketing offer growth opportunities and cost-saving potential for the company.
Challenges include managing the transition of company-owned clinics and balancing marketing expenses with revenue growth objectives.
Overall, The Joint Corp. is well-positioned to capitalize on its operational strengths and market opportunities for sustained growth and success.

The Joint Corp. triples franchise sales and boosts financial performance

The Joint Corp. delivered strong financial performance in Q1 2024, marked by revenue growth, improved bottom line, and significant franchise sales growth, supported by robust marketing strategies.
While facing potential risks and challenges, the company's focus on EBITDA, franchise expansion, and talent development positions it well for future growth and operational excellence.
Opportunities in marketing innovation, talent development, and operational efficiency present avenues for sustained growth and value creation, aligning with the company's commitment to performance and brand enhancement.
Overall, The Joint Corp.'s Q1 2024 earnings call highlighted a strategic roadmap for success, emphasizing growth, excellence in patient care, and financial transparency to drive shareholder value.

The Joint Corp. reports revenue growth and strategic focus on clinics

The Joint Corp. reported positive revenue growth in Q2 2024, driven by same-store comps and operational improvements.
While facing financial challenges and impact on franchise sales, the company's strategic focus on clinic optimization and patient loyalty is a key strength.
Future opportunities lie in expanding the clinic network, enhancing profitability, and driving patient loyalty through innovative strategies.
Overall, The Joint Corp. is positioned for growth with a strong foundation of clinics and a focus on improving financial performance and patient experiences.

Joint Corp (JYNT) reports robust Q3 performance amidst operational enhancements

Joint Corp's Q3 2024 earnings call highlighted strong performance metrics, a strategic focus on patient care and operational efficiency, and challenges related to consumer headwinds and refranchising efforts. The company is well-positioned to capitalize on growth opportunities by leveraging its infrastructure and exploring new service offerings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Joint Corp. engages in the development, ownership, operation, support, and management of chiropractic clinics. It operates through the Corporate Clinics and Franchise Operations segments. The Corporate Clinics segment consists of the operating activities of the company-owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar, and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.

SCOTTSDALE, Ariz., Feb. 14, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its fourth quarter and year-end 2021 financial results on Thursday, February 24, 2022, after the market close. President and CEO Peter D. Holt and CFO Jake Singleton will hold a conference call at 5:00 p.m. ET that day to discuss the results.

The Joint Corp. to Host Conference Call on Thursday, February 24th to Discuss Fourth Quarter and Year-end 2021 Results

The Joint Corp. (JYNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will The Joint Corp. (JYNT) Beat Estimates Again in Its Next Earnings Report?

SCOTTSDALE, Ariz., Jan. 28, 2022 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, continues to gain recognition for its growing retail healthcare business model.

The Joint Chiropractic Rings in 2022 with Prestigious Recognitions in Franchising

SCOTTSDALE, Ariz., Jan. 28, 2022 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announces a sponsorship agreement with University of Nevada Athletics.

The Joint Chiropractic Becomes the Official Chiropractic Partner of Nevada Athletics

SCOTTSDALE, Ariz., Jan. 25, 2022 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, welcomes Charles Nelles into the newly-created position of Chief Technology Officer.

The Joint Corp. Hires Chief Technology Officer

Turtle Beach

Lazydays

One Stop Systems

Ammo

Talos Energy Inc

Although several discounts are in play due to recent market volatility, these small-cap stocks may deliver a much bigger bang for your buck. The post 7 Small-Cap Stocks to Buy for Big Results in 2022 appeared first on InvestorPlace.

7 Small-Cap Stocks to Buy for Big Results in 2022

SCOTTSDALE, Ariz., Jan. 21, 2022 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, and Atlanta United recently signed an agreement naming The Joint as the Official Chiropractic Partner of Atlanta United.

The Joint Chiropractic is Named the Official Chiropractic Partner of Atlanta United

The Joint Corp. (JYNT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Joint Corp. (JYNT) Moves 9% Higher: Will This Strength Last?

- Grows Annual System-Wide Sales 39%, Compared to 2020 - - Increases Comp Sales of 29%, Compared to 2020 - - Opens 130 New Clinics, Up from 73 in 2020 -

The Joint Corp. Reports 2021 Operating Metrics

SCOTTSDALE, Ariz., Dec. 23, 2021 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic®  network, announces the opening of its 700th location nationwide.

The Joint Chiropractic Reaches New Growth Milestone

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Joint Corp. (NASDAQ: JYNT) resulting from allegations that Joint may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Joint securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages The Joint Corp. Investors with Losses to Inquire About Class Action Investigation - JYNT

Los Angeles, California--(Newsfile Corp. - December 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Joint Corp. ("Joint" or "the Company") (NASDAQ: JYNT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Joint is the subject of a research report published by The...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against The Joint Corp. and Encourages Investors with Losses to Contact the Firm

SCOTTSDALE, Ariz., Nov. 15, 2021 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, is number one on the Forbes 2022 America's Best Small Companies list.

The Joint Chiropractic Earns Top Spot on Forbes' 2022 America's Best Small Companies List

The Joint Corp (JYNT) CEO Peter Holt on Q3 2021 Results - Earnings Call Transcript

The Joint Corp. (JYNT) delivered earnings and revenue surprises of 225.00% and 7.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Joint Corp. (JYNT) Q3 Earnings and Revenues Beat Estimates

- Grows Revenue 36%, System-wide Sales 37%, and  System-wide Comp Sales 27%, Compared to Q3 2020 - - Sold 44 Franchise Licenses, Compared to 30 in Q3 2020 - - Opened 33 Clinics, Including 5 Greenfields, Bringing the Total Corporate Count to 83 at Quarter End - - Raised 2021 Guidance on Franchise Openings, Revenue and Adjusted EBITDA -

The Joint Corp. Reports Third Quarter 2021 Financial Results

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Joint Corp. ("Joint" or the "Company") (NASDAQ: JYNT).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Joint Corp. - JYNT

Los Angeles, California--(Newsfile Corp. - November 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Joint Corp. ("Joint" or "the Company") (NASDAQ: JYNT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Joint is the subject of a research report published by The...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Joint Corp. and Encourages Investors with Losses to Contact the Firm

- Promotes Marketing and Brand Leader to Spearhead Next Phase of Marketing Innovation -

The Joint Corp. Names Jason Greenwood CMO

The Joint is an exciting growth stock. But it's also a great defensive stock if the economy heads south.

This Fast-Growing Healthcare Stock Will Win Even if the Economy Goes Bad

Franchise Brand Ranks #3 and Takes the Top Healthcare Spot Franchise Brand Ranks #3 and Takes the Top Healthcare Spot

The Joint Corp. Named to Fortune's 2021 100 Fastest-Growing Companies List

Alkermes

BioNTech SE

Bruker

Heska

Inmode Ltd

Prothena

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.

7 A-Rated Healthcare Stocks to Buy for the Long Haul

Boston, Massachusetts--(Newsfile Corp. - October 25, 2021) -  Block & Leviton is investigating Joint Corp. (NASDAQ: JYNT) for potential securities law violations. Investors who have lost money in their Joint Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/jynt.What is this all about?On October 7, 2021, The Bear Cave issued a report alleging problems at Joint Corp., indicating that the franchisor of chiropractic...

JOINT INVESTIGATION: Block & Leviton Is Investigating Joint Corp. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

SCOTTSDALE, Ariz., Oct. 21, 2021 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its third quarter 2021 financial results on Thursday, November 4, 2021, after the market close. President and CEO Peter D. Holt and CFO Jake Singleton will hold a conference call at 5:00 p.m. ET that day to discuss the results.

The Joint Corp. to Host Conference Call on Thursday, November 4th to Discuss Third Quarter 2021 Results

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Joint Corp. (NASDAQ: JYNT) resulting from allegations that Joint may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Joint securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

JYNT INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages The Joint Corp. Investors with Losses to Inquire About Class Action Investigation - JYNT

News for Joint Stock (JYNT)